Founded in 2007 by renowned cardiologist and medical device entrepreneur Dr. John B. Simpson, Avinger seeks to radically improve the treatment of vascular disease through the development ...
The biggest medical advance since the x-ray? Incredible hyperbole.
LITTLE ROCK, AR - It's no bigger than a strand of hair, but it's changing the way cardiologists at the Arkansas Heart Hospital operate. "It's like working with your eyes open as opposed to working with your eyes closed," said Dr. Ian Cawich, one of the first cardiologists in the U.S. to use the device. For the first time in the country, doctors at the Arkansas Heart Hospital are operating with the Ocelot - the first ever catheter with a camera on the end allowing doctors to see inside ...
John B. Simpson is a Cardiologist and Entrepreneur. He was recently Chief Executive Officer and Founder of FoxHollow Technologies. Dr. Simpson founded our Company in September 1996 and has served as our Chief Executive Officer since January 2006. Dr. Simpson has served as a member of our Board since September 1996. From May 2004 to December 2005, Dr. Simpson also served as a consultant to our Company and from October 1996 to July 1997, Dr. Simpson served as our President. Since March 2000, Dr. Simpson has served in various positions at De Novo Ventures, a venture capital fund, including Managing Director and Clinical Director. Since 1983, Dr. Simpson has been a Partner at Cardiovascular Medicine and Coronary Interventions, a cardiology physician group. Prior to founding our Company, Dr. Simpson founded several other interventional cardiology companies, including Perclose, a manufacturer of femoral artery access site closure devices, Devices for Vascular Intervention, a manufacturer of atherectomy devices, and Advanced Cardiovascular Systems, a manufacturer of balloon angioplasty devices. Dr. Simpson is a Professor of Clinical Medicine at Stanford University. Dr. Simpson holds a B.S. in Agriculture from Ohio State University, an M.D. from the Duke University School of Medicine and an M.S. and a Ph.D. in Biomedical Science from the University of Texas.
With its smaller profile and longer length, Ocelot | PIXL is designed to bring all the benefits of Ocelot to help physicians treat more patients with smaller arteries...Because Ocelot | PIXL, like the original Ocelot catheter, uses real-time intravascular imaging via optical coherence tomography (OCT), I’m confident more legs will be saved, and more patients will walk home happy.In Avinger Receives FDA Clearance for Ocelot | PIXL
It has taken my entire career to get to this moment...Incorporating intravascular OCT into therapeutic devices has been the biggest priority here at Avinger. We have amazing investors who have allowed us to demonstrate how revolutionary Avinger can be. I’m so proud of our employees, all the physicians and hospitals around the world that helped us bring this amazing technology to the patients in the US.In Avinger’s Ocelot System is FDA Cleared
The enrollment rate was well ahead of our projected schedule.In Avinger Reports Results of Clinical Study Evaluating New Imaging Catheter Designed To Help Cross CTOs in Patients with Peripheral Artery Disease (PAD)
Ocelot was designed to enable more informed treatment decisions, and the more information a physician has available during a procedure, the better we can help treat those patients.In Avinger Raises $33 Million in Series D Financing
We are pleased to reach this significant milestone ahead of schedule and already see promising preliminary data collected...We appreciate the patient participation and dedicated efforts of our employees, physician investigators and their research staffs. Together, we are now one step closer to bringing the Ocelot technology to patients who need it most.In Avinger Completes Enrollment of PAD-Focused CONNECT II Global Clinical Trial
We hope that physicians using Ocelot can now help prevent even more leg amputations in people suffering from PAD...The team here at Avinger has been working really hard and I’m excited to see our efforts now go directly towards helping these patients.In Avinger Enrolls First U.S. Pad Patient in CONNECT II Global Clinical Trial - Intravascular imaging further prevents leg amputations
This is a major milestone for Avinger and a true testament to the perseverance of all our employees and investors. Many people said we couldn't do it...Ocelot and CONNECT II is our first step toward incorporating intravascular imaging into therapeutic catheters. We truly believe this will revolutionize the treatment of vascular disease and amputation prevention.In Avinger Enrolls First European PAD Patient in CONNECT II Global Clinical Trial
We're looking forward to transmitting two live cases from Muenster to this year's LINC audience.In Avinger to Perform Two Live Ocelot Cases at LINC Conference in Leipzig, Germany
Early EU commercial cases are showing remarkable patient outcomes...Avinger’s global product portfolio has already helped physicians treat more than 5000 patients suffering from PAD. We’re committed to making sure all people suffering from this epidemic can have access to our advanced technologies.In Avinger Raises $22.5 Million in Series C Financing
Ocelot CE Mark is a long anticipated milestone for Avinger and a much larger milestone for me professionally. I’ve been working on uniting intravascular guidance with therapeutic products for 30 years and I’m humbled that we’ve been able to achieve this at Avinger... This speaks volumes about our team at Avinger and their dedication to patient care. Ocelot CE Mark is a pivotal step that allows us to immediately help more patients suffering from PAD.”In Avinger Receives CE Mark Approval for Its Ocelot Catheter That Incorporates Real-Time Intravascular Guidance Using Optical Coherence Tomography (OCT)
Avinger's Dr. John B. Simpson has invented a technology that enables Austin Heart's team of interventional cardiologists to treat PAD patients with more precision than ever before possible...The trial is hoping to help patients regain mobility and improve quality of life, and in the process many patients might be spared unnecessary amputations. Austin Heart is committed to saving the legs of our PAD patients so they can return to a healthy life.In Austin Heart Enrolls PAD Patient in Avinger’s CONNECT II Global Clinical Trial